AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05502146
Drug: Noradrenaline Bitartrate
RxNorm normalized name: Noradrenaline bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of norepinephrine 8 mcg will be administered for management of maternal hypotension.
Trial: NCT06136598
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet to be taken orally as a rescue medication.
Trial: NCT00034957
Drug: Investigational drug
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00611845
Drug: Aprotinin (Trasylol, BAYA0128)
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trasylol at either 1,000,000 KIU or 2,000,000 KIU
Trial: NCT06618079
Drug: HUC2-565-B, HUC2-565-A and HUC2-565-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days.
Trial: NCT05161208
Drug: Placebo (vehicle) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
Trial: NCT06058130
Drug: Anticoagulant Oral
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation alone
Trial: NCT04398485
Drug: ION251
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ION251 administered by IV infusion
Trial: NCT06483048
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04183738
Drug: NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined.
Trial: NCT06395610
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeated doses of oral Erythromycin
Trial: NCT05678270
Drug: ICP-192
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-192 is a round, uncoated tablet, 5mg, orally.
Trial: NCT05118776
Drug: ASC40 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC40 tablets administered orally once daily
Trial: NCT06225856
Drug: YY201
RxNorm normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'YY201'. Drug abbreviations can vary and may not be standardized, so without more context about the specific drug or clinical trial, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration under fasting state.
Trial: NCT05118776
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally once daily.
Trial: NCT04591990
Drug: Administration of placebo AVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo AVP
Trial: NCT04591990
Drug: Administration of placebo hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo hydrocortisone
Trial: NCT04591990
Drug: Administration of hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration of hydrocortisone
Trial: NCT05481528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of placebo
Trial: NCT05087914
Drug: Carbidopa-Levodopa (100mg/25mg):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
Trial: NCT05087914
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
Trial: NCT05603195
Drug: REGN7508 (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered sequential, ascending single intravenous (IV) dose
Trial: NCT05603195
Drug: Matching Placebo (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered sequential, ascending single intravenous (IV) dose
Trial: NCT05603195
Drug: Matching Placebo (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered sequential, ascending single subcutaneous (SC) dose
Trial: NCT05985200
Drug: Placebo matching BI 3032950
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 3032950
Trial: NCT00002090
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04982692
Drug: intravaginal prasterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
Trial: NCT04982692
Drug: Placebo ovules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
Trial: NCT05024097
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
Trial: NCT06653465
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, which has similarly effects with NSAIDs in terms of inhibition of cyclooxygenase COX1, COX2 and COX3, is widely used as adjuvant for perioperative multimodal analgesia.
Trial: NCT06648265
Drug: Tumescent solution with dilute lidocaine and epinephrine
RxNorm normalized name: epinephrine / lidocaine Injectable Solution [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm infiltration with traditional Klein\&#39;s tumescent solution
Trial: NCT00673751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06579053
Drug: Spironolactone Tablets (Test)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take one test tablet each period
Trial: NCT06579053
Drug: Spironolactone Tablets (Reference)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take one reference tablet each period
Trial: NCT06004856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily (QD)
Trial: NCT06015503
Drug: PLB1004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLB1004 is a capsule in the form of 80mg and 40mg.
Trial: NCT06032052
Drug: Single drug chemotherapy plus immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine. Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer. Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on
Trial: NCT05581303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given by subcutaneous injection once every 12 weeks (Q12W).
Trial: NCT05413369
Drug: IDegAsp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, by subcutaneous injection
Trial: NCT06016010
Drug: USL Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USL Placebo
Trial: NCT06699966
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.
Trial: NCT06699966
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.
Trial: NCT04604275
Drug: Sucrase
RxNorm normalized name: Sucrase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
Trial: NCT06683651
Drug: STN1013800 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product: 0.1% STN1013800 ophthalmic solution
Trial: NCT06683651
Drug: STN1013800 ophthalmic solution Liquid Base, without STN1013800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control: STN1013800 ophthalmic solution Liquid Base, without STN1013800
Trial: NCT06699407
Drug: Qishenyiqi dripping pills
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Trial: NCT06699407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 bag once, three times a day, 12 months
Trial: NCT05885035
Drug: Calcium Hydroxyapatite
RxNorm normalized name: Calcium hydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.
Trial: NCT05300802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.
Trial: NCT06144424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once Daily
Trial: NCT06554509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT06152497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: NCT04021121
Drug: Standard dose RIF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIF 10 mg/kg/day
Trial: NCT06219824
Drug: premixed Bio-ceramic MTA
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pulpotomy treatment will be done and the premixed bioceramic MTA will be applied in the pulp chamber
Trial: NCT06219824
Drug: Conventional MTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pulpotomy treatment will be done and powder and liquid MTA will be mixed and applied in the pulp chamber
Trial: NCT06520982
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infused intra-arterially in a dose-response fashion
Trial: NCT06520982
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infused intra-arterially in a dose-response fashion
Trial: NCT05507476
Drug: Epinephrine topical 1:100,000 Nasal Packs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal gland via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery.
Trial: NCT05655286
Drug: 38% SDF treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with active caries will receive 38% silver diamine fluoride treatment
Trial: NCT04654988
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine: 2 mg/kg daily for 12 months
Trial: NCT04654988
Drug: Placebo Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo Azathioprine
Trial: NCT05814809
Drug: JP-1366 20mg tablet
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T : JP-1366 20mg tablet
Trial: NCT05814809
Drug: JP-1366 20mg capsule
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R : JP-1366 20mg capsule
Trial: NCT05296044
Drug: JT-003 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take the investigational products once a day for 24 weeks.
Trial: NCT05793450
Drug: IBI362
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0mg, SC, single dose
Trial: NCT06489327
Drug: melatonin (Circadin ®) 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral melatonin at a dose of 0.2 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
Trial: NCT06489327
Drug: melatonin (Circadin ®) 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral melatonin at a dose of 0.4 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
Trial: NCT06489327
Drug: placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral placebo as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
Trial: NCT05347238
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.
Trial: NCT05347238
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
Trial: NCT05115344
Drug: flonoltinib 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Trial: NCT05115344
Drug: flonoltinib 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Trial: NCT05115344
Drug: flonoltinib 225mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Trial: NCT05115344
Drug: flonoltinib 325mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 case,Increasing dose,Take the medicine once on D1,D5 -21.
Trial: NCT06620393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% 100ml
Trial: NCT04707703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo every 8 hours for 6 doses followed by intravenous placebo once daily for up to 28 days
Trial: NCT00095641
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06074809
Drug: Modified Guizhi Fuling granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.
Trial: NCT04181515
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo stressor
Trial: NCT04181515
Drug: Yohimbine + Hydrocortisone
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 54mg + Hydrocortisone 20mg
Trial: NCT04803734
Drug: Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI, 2 puffs, single dose, fasting
Trial: NCT05700916
Drug: Milk Polar Lipid-Rich Dairy Powder
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effects of the addition of 6.5 g of milk polar lipids to dairy powder.
Trial: NCT06008197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo
Trial: NCT01641796
Drug: Paromomycin
RxNorm normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin Topical Cream applied to all lesions once a day for 20 days
Trial: NCT06618820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose consists of three microcrystalline cellulose capsules.
Trial: NCT05959096
Drug: LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05067439
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of 100 mg
Trial: NCT06472531
Drug: INR101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT
Trial: NCT06472531
Drug: INR101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT~* 7±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT
Trial: NCT06293989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups:Placebo . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
Trial: NCT04871061
Drug: Conventional opioid analgesia (Fentanyl)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standardised intravenous opioid
Trial: NCT06410703
Drug: CAN1012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W
Trial: NCT04874233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active study drug N = 20
Trial: NCT04804267
Drug: LINZESS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
Trial: NCT04804267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo orally once daily
Trial: NCT06499168
Drug: neoadjuvant chemotherapy: anthracycline based chemotherapy and taxans before surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In locally advanced breast cancer patients who will receive neoadjuvant chemotherapy formalin fixed paraffin embedded tissue specimen of the baseline TCNB of locally advanced breast cancer will be obtained from pathology laboratory, Pathology Department, Assiut University.~* Histological diagnosis of H\&E stained sections will be confirmed.~* Immunohistochemical staining for CD10 .~* Baseline clinicopathological features of patients who will receive neoadjuvant chemotherapy will be collected from patients' records.~* Correlation between CD10 expression and the baseline clinicopathological features with the response to neoadjuvant chemotherapy.
Trial: NCT06620796
Drug: second-line group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK112+AK104+paclitaxel
Trial: NCT05729386
Drug: GC2129A(Period 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin and Metformin Hydrochloride Tablet
Trial: NCT05729386
Drug: GC2129A(Period 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin and Metformin Hydrochloride Tablet
Trial: NCT05148234
Drug: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Higher Risk (HR) Myelodysplastic Syndromes (MDS) cohort, the study drug of BMS-986253 will be given in combination with standard of care (SOC) Food and Drug Administration (FDA)-approved DNMTi by mouth (PO) decitabine and cedazuridine according to guidelines outlined in FDA product label. Standard of care (SOC) DNMTi will be administered via oral route once daily starting Day (D)2 of each treatment cycle through D6.
Trial: NCT06390774
Drug: SSGJ-705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 and anti-HER2 bispecific antibody
Trial: NCT06444269
Drug: microbubble CEUS Contrast Enhanced Ultrasound (CEUS)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microbubble Contrast non-FDA approved for route of administration
Trial: NCT06668298
Drug: Sulfentanil
RxNorm normalized name: Sulfentanil citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The analgesic regimen for the sufentanil group is sufentanil 2 µ g · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
Trial: NCT05521256
Drug: NNC0113-6856
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NN0113-6856 orally or intravenously.
Trial: NCT05521256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.